As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

As of March 20, 2023, around 391 doses of COVID-19 vaccines per 100 people in Cuba had been administered, one of the highest COVID-19 vaccine dose rates of any country worldwide. This statistic shows the rate of COVID-19 vaccine doses administered worldwide as of March 20, 2023, by country or territory.

As of December 23, 2022, around 80 percent of the population of the United States had been given at least one dose of a COVID-19 vaccination. This statistic shows the percentage of population in select countries and territories worldwide that had received a COVID-19 vaccination as of December 23, 2022.

IntroductionIn relatively wealthy countries, substantial between-country variability in COVID-19 vaccination coverage occurred. We aimed to identify influential national-level determinants of COVID-19 vaccine uptake at different COVID-19 pandemic stages in such countries.MethodsWe considered over 50 macro-level demographic, healthcare resource, disease burden, political, socio-economic, labor, cultural, life-style indicators as explanatory factors and coverage with at least one dose by June 2021, completed initial vaccination protocols by December 2021, and booster doses by June 2022 as outcomes. Overall, we included 61 European or Organisation for Economic Co-operation and Development (OECD) countries. We performed 100 multiple imputations correcting for missing data and partial least squares regression for each imputed dataset. Regression estimates for the original covariates were pooled over the 100 results obtained for each outcome. Specific analyses focusing only on European Union (EU) or OECD countries were also conducted.ResultsHigher stringency of countermeasures, and proportionately more older adults, female and urban area residents, were each strongly and consistently associated with higher vaccination rates. Surprisingly, socio-economic indicators such as gross domestic product (GDP), democracy, and education had limited explanatory power. Overall and in the OECD, greater perceived corruption related strongly to lower vaccine uptake. In the OECD, social media played a noticeable positive role. In the EU, right-wing government ideology exhibited a consistently negative association, while cultural differences had strong overall influence.ConclusionRelationships between country-level factors and COVID-19 vaccination uptake depended on immunization stage and country reference group. Important determinants include stringency, population age, gender and urbanization, corruption, government ideology and cultural context.

The surge of COVID-19 infections has been fueled by new SARS-CoV-2 variants, namely Alpha, Beta, Gamma, Delta, and so forth. The molecular mechanism underlying such surge is elusive due to the existence of 28 554 unique mutations, including 4 653 non-degenerate mutations on the spike protein. Understanding the molecular mechanism of SARS-CoV-2 transmission and evolution is a prerequisite to foresee the trend of emerging vaccine-breakthrough variants and the design of mutation-proof vaccines and monoclonal antibodies. We integrate the genotyping of 1 489 884 SARS-CoV-2 genomes, a library of 130 human antibodies, tens of thousands of mutational data, topological data analysis, and deep learning to reveal SARS-CoV-2 evolution mechanism and forecast emerging vaccine-breakthrough variants. We show that prevailing variants can be quantitatively explained by infectivity-strengthening and vaccine-escape (co-)mutations on the spike protein RBD due to natural selection and/or vaccination-induced evolutionary pressure. We illustrate that infectivity strengthening mutations were the main mechanism for viral evolution, while vaccine-escape mutations become a dominating viral evolutionary mechanism among highly vaccinated populations. We demonstrate that Lambda is as infectious as Delta but is more vaccine-resistant. We analyze emerging vaccine-breakthrough comutations in highly vaccinated countries, including the United Kingdom, the United States, Denmark, and so forth. Finally, we identify sets of comutations that have a high likelihood of massive growth: [A411S, L452R, T478K], [L452R, T478K, N501Y], [V401L, L452R, T478K], [K417N, L452R, T478K], [L452R, T478K, E484K, N501Y], and [P384L, K417N, E484K, N501Y]. We predict they can escape existing vaccines. We foresee an urgent need to develop new virus combating strategies.

State-by-state data on United States COVID-19 vaccinations data

Acknowledgement and License

All data are produced by Our World in Data are completely open access under the Creative Commons BY license. You have the permission to use, distribute, and reproduce these in any medium, provided the source and authors are credited. In the case of our vaccination dataset, please give the following citation:

Mathieu, E., Ritchie, H., Ortiz-Ospina, E. et al. A global database of COVID-19 vaccinations. Nat Hum Behav (2021). https://doi.org/10.1038/s41562-021-01122-8

Data Set Column Details

location : name of the state or federal entity. date: date of the observation. total vaccinations: total number of doses administered. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses). If a person receives one dose of the vaccine, this metric goes up by 1. If they receive a second dose, it goes up by 1 again. total vaccinations per hundred: total vaccinations per 100 people in the total population of the state. daily vaccinations raw: daily change in the total number of doses administered. It is only calculated for consecutive days. This is a raw measure provided for data checks and transparency, but we strongly recommend that any analysis on daily vaccination rates be conducted using daily vaccinations instead. daily vaccinations: new doses administered per day (7-day smoothed). For countries that don't report data on a daily basis, we assume that doses changed equally on a daily basis over any periods in which no data was reported. This produces a complete series of daily figures, which is then averaged over a rolling 7-day window. An example of how we perform this calculation can be found here. daily vaccinations per million: daily vaccinations per 1,000,000 people in the total population of the state. people vaccinated: total number of people who received at least one vaccine dose. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same. people vaccinated per hundred: people vaccinated per 100 people in the total population of the state. people fully vaccinated: total number of people who received all doses prescribed by the initial vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1. people fully vaccinated per hundred: people fully vaccinated per 100 people in the total population of the state. total distributed: cumulative counts of COVID-19 vaccine doses recorded as shipped in CDC's Vaccine Tracking System. total distributed per hundred: cumulative counts of COVID-19 vaccine doses recorded as shipped in CDC's Vaccine Tracking System per 100 people in the total population of the state. share doses used: share of vaccination doses administered among those recorded as shipped in CDC's Vaccine Tracking System. total boosters: total number of COVID-19 vaccination booster doses administered (doses administered beyond the number prescribed by the initial vaccination protocol) total boosters per hundred: total boosters per 100 people in the total population.

Time Span

20th Dec 2020 to 28th Dec 2022

Context

The data is collected from OWID (Our World in Data) GitHub repository, which is updated on daily bases.

Content

This dataset contains only one file vaccinations.csv, which contains the records of vaccination doses received by people from all the countries. * location: name of the country (or region within a country). * iso_code: ISO 3166-1 alpha-3 – three-letter country codes. * date: date of the observation. * total_vaccinations: total number of doses administered. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses). If a person receives one dose of the vaccine, this metric goes up by 1. If they receive a second dose, it goes up by 1 again. * total_vaccinations_per_hundred: total_vaccinations per 100 people in the total population of the country. * daily_vaccinations_raw: daily change in the total number of doses administered. It is only calculated for consecutive days. This is a raw measure provided for data checks and transparency, but we strongly recommend that any analysis on daily vaccination rates be conducted using daily_vaccinations instead. * daily_vaccinations: new doses administered per day (7-day smoothed). For countries that don't report data on a daily basis, we assume that doses changed equally on a daily basis over any periods in which no data was reported. This produces a complete series of daily figures, which is then averaged over a rolling 7-day window. An example of how we perform this calculation can be found here. * daily_vaccinations_per_million: daily_vaccinations per 1,000,000 people in the total population of the country. * people_vaccinated: total number of people who received at least one vaccine dose. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same. * people_vaccinated_per_hundred: people_vaccinated per 100 people in the total population of the country. * people_fully_vaccinated: total number of people who received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1. * people_fully_vaccinated_per_hundred: people_fully_vaccinated per 100 people in the total population of the country.

Note: for people_vaccinated and people_fully_vaccinated we are dependent on the necessary data being made available, so we may not be able to make these metrics available for some countries.

Acknowledgements

This data collected by Our World in Data which gets updated daily on their Github.

Inspiration

Possible uses for this dataset could include: - Sentiment analysis in a variety of forms - Statistical analysis over time.

Context

Data is collected daily from Our World in Data GitHub repository for covid-19, merged and uploaded.

Content

The data contains the following information: * **Country **- this is the country for which the vaccination information is provided;
* Country ISO Code - ISO code for the country;
* **Date **- date for the data entry; for some of the dates we have only the daily vaccinations, for others, only the (cumulative) total;
* Total number of vaccinations - this is the absolute number of total immunizations in the country;
* Total number of people vaccinated - a person, depending on the immunization scheme, will receive one or more (typically 2) vaccines; at a certain moment, the number of vaccination might be larger than the number of people;
* Total number of people fully vaccinated - this is the number of people that received the entire set of immunization according to the immunization scheme (typically 2); at a certain moment in time, there might be a certain number of people that received one vaccine and another number (smaller) of people that received all vaccines in the scheme;
* Daily vaccinations (raw) - for a certain data entry, the number of vaccination for that date/country;
* Daily vaccinations - for a certain data entry, the number of vaccination for that date/country;
* Total vaccinations per hundred - ratio (in percent) between vaccination number and total population up to the date in the country;
* Total number of people vaccinated per hundred - ratio (in percent) between population immunized and total population up to the date in the country;
* Total number of people fully vaccinated per hundred - ratio (in percent) between population fully immunized and total population up to the date in the country;
* Number of vaccinations per day - number of daily vaccination for that day and country;
* Daily vaccinations per million - ratio (in ppm) between vaccination number and total population for the current date in the country;
* Vaccines used in the country - total number of vaccines used in the country (up to date);
* Source name - source of the information (national authority, international organization, local organization etc.);
* Source website - website of the source of information;

Acknowledgements

I would like to specify that I am only making available Our World in Data collected data about vaccinations to Kagglers. My contribution is very small, just daily collection, merge and upload of the updated version, as maintained by Our World in Data in their GitHub repository.

Inspiration

Track COVID-19 vaccination in the World, answer instantly to your questions:
- Which country is using what vaccine?
- In which country the vaccination programme is more advanced?
- Where are vaccinated more people per day? But in terms of percent from entire population ?

Dataset contains: Latest worldwide vaccination status of all the countries till 08th Jan 2023.

Features: Country-Name of the country Pct. of population Vaccinated-Percentage of population Vaccinated Pct. of population Fully vaccinated-Percentage of population Fully vaccinated Additional Doses Per 100 people-Number of additional doses per 100 people Additional Doses Total-Number of total additional doses Doses administered Per 100 people-Number of vaccine doses administered per 100 people Total Doses administered-Total number of doses administered

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by a virus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first known case was identified in Wuhan, China, in December 2019.The disease quickly spread worldwide, resulting in the COVID-19 pandemic.

Vaccines save millions of lives each year and a COVID-19 vaccine could save yours. The COVID-19 vaccines are safe and effective, providing strong protection against serious illness and death. WHO reports that unvaccinated people have at least 10 times higher risk of death from COVID-19 than someone who has been vaccinated.The COVID-19 vaccines are highly effective, but no vaccine provides 100 per cent protection. Some people will still get ill from COVID-19 after vaccination or pass the virus onto someone else. Therefore, it is important to continue practicing safety precautions to protect yourself and others, including avoiding crowded spaces, physical distancing, hand washing and wearing a mask.

Estimated regression models of percentage of population fully vaccinated at 6, 12, 18 and 24 months post global roll-out.

By August 2024, Cuba had administered the largest number of vaccines against COVID-19 per 100 inhabitants in the Latin American region, followed by Chile and Peru. According to recent estimates, the Caribbean country applied around 410 doses per 100 population, accounting for one of the largest vaccination rates observed not only in the Latin American region, but worldwide. In comparison, Haiti registered the lowest vaccination rate within the region, with only 5.87 doses administered per 100 inhabitants. Booster shots started To reinforce the immune protection against the fast spread of the SARS-CoV-2, governments began to introduce booster shots in their immunization programs aiming at strengthening people’s immune response against new contagious COVID-19 variants. In Latin America, Cuba was leading on booster shots relative to its population among a selection of countries, with around 88 percent of the population receiving the extra dose. In comparison, these numbers are higher than those for the European Union and the United States. Pharmaceutical research continues As Omicron becomes more prominent worldwide, and recombinant variants emerge, research efforts to prevent and control the disease continue to progress. As of June 2022, there were around 2,700 clinical trials to treat COVID-19 and 1,752 COVID-19 vaccines trials in clinical development. Other studies were focused on mild, moderate and severe COVID-19, complication support, and post-COVID symptoms, among others.For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

About this Dataset

The data contains the following information:

Country- this is the country for which the vaccination information is provided; Country ISO Code - ISO code for the country; Date - date for the data entry; for some of the dates we have only the daily vaccinations, for others, only the (cumulative) total; Total number of vaccinations - this is the absolute number of total immunizations in the country; Total number of people vaccinated - a person, depending on the immunization scheme, will receive one or more (typically 2) vaccines; at a certain moment, the number of vaccination might be larger than the number of people; Total number of people fully vaccinated - this is the number of people that received the entire set of immunization according to the immunization scheme (typically 2); at a certain moment in time, there might be a certain number of people that received one vaccine and another number (smaller) of people that received all vaccines in the scheme; Daily vaccinations (raw) - for a certain data entry, the number of vaccination for that date/country; Daily vaccinations - for a certain data entry, the number of vaccination for that date/country; Total vaccinations per hundred - ratio (in percent) between vaccination number and total population up to the date in the country; Total number of people vaccinated per hundred - ratio (in percent) between population immunized and total population up to the date in the country; Total number of people fully vaccinated per hundred - ratio (in percent) between population fully immunized and total population up to the date in the country; Number of vaccinations per day - number of daily vaccination for that day and country; Daily vaccinations per million - ratio (in ppm) between vaccination number and total population for the current date in the country; Vaccines used in the country - total number of vaccines used in the country (up to date); Source name - source of the information (national authority, international organization, local organization etc.); Source website - website of the source of information;

Tasks: Track the progress of COVID-19 vaccination What vaccines are used and in which countries? What country is vaccinated more people? What country is vaccinated a larger percent from its population?

This data is valuble in relation to the health, financial, and engineering sectors.

Category

Health & Medicine

Keywords

Health,Medicine,covid-19,dataset,progress

Row Count

5824

Price

$120.00

The average for 2022 based on 187 countries was 84 percent. The highest value was in Antigua and Barbuda: 99 percent and the lowest value was in North Korea: 0 percent. The indicator is available from 1980 to 2022. Below is a chart for all countries where data are available.

BackgroundThe rapid development and rollout of COVID-19 vaccines helped reduce the pandemic’s mortality burden. The vaccine rollout, however, has been uneven; it is well known that vaccination rates tend to be lower in lower income countries. Vaccine uptake, however, ultimately depends on the willingness of individuals to get vaccinated. If vaccine confidence is low, then uptake will be low, regardless of country income level. We investigated the impact on country-level COVID-19 vaccination rates of both national income and vaccine hesitancy.MethodsWe estimated a linear regression model of COVID-19 vaccine uptake across 145 countries; this cross-sectional model was estimated at each of four time points: 6, 12, 18, and 24 months after the onset of global vaccine distribution. Vaccine uptake reflects the percentage of the population that had completed their primary vaccination series at the time point. Covariates include per capita GDP, an estimate of the percentage of country residents who strongly disagreed that vaccines are safe, and a variety of control variables. Next, we estimated these models of vaccine uptake by country income (countries below, and above the international median per capita GDP) to examine whether the impact of vaccine hesitancy varies by country income.ResultsWe find that GDP per capita has a pronounced impact on vaccine uptake at 6 months after global rollout. After controlling for other factors, there was a 22 percentage point difference in vaccination rates between the top 20% and the bottom 20% of countries ranked by per capita GDP; this difference grew to 38% by 12 months. The deleterious impact of distrust of vaccine safety on vaccine uptake became apparent by 12 months and then increased over time. At 24 months, there was a 17% difference in vaccination rates between the top 20% and the bottom 20% of countries ranked by distrust. The income stratified models reveal that the deleterious impact of vaccine distrust on vaccine uptake at 12 and 24 months is particularly evident in lower income countries.ConclusionsOur study highlights the important role of both national income and vaccine hesitancy in determining COVID-19 vaccine uptake globally. There is a need to increase the supply and distribution of pandemic vaccines to lower-income countries, and to take measures to improve vaccine confidence in these countries.

This dataset provides values for CORONAVIRUS VACCINATION RATE reported in several countries. The data includes current values, previous releases, historical highs and record lows, release frequency, reported unit and currency.

Data on COVID-19 (coronavirus) Vaccination

Our complete COVID-19 dataset is a collection of the COVID-19 data. We will update it daily throughout the duration of the COVID-19 pandemic. It includes the following data:

The complete Our World in Data COVID-19 dataset

The CSV and files follow a format of 1 row per location and date. This version is split by country ISO code, with static variables and an array of daily records.

The variables represent all of our main data related to confirmed cases, deaths, hospitalizations, and testing, as well as other variables of potential interest.

Confirmed cases

Confirmed deaths

Hospital & ICU

As of March 15, 2023, Seychelles was the African country with the highest coronavirus (COVID-19) vaccination rate, with around 205 doses administered per 100 individuals. Mauritius and Rwanda followed with 201 and 190 doses per 100 people, respectively. Ranking fourth, Morocco had a vaccination rate of approximately 148 doses per 100 people, registering the third-highest number of inoculations after Egypt and Nigeria. In South Africa, the most affected country on the continent, the vaccination rate instead reached around 64 per 100 population.

How did Africa obtain the vaccines?

Vaccines in Africa were obtained in different ways. African nations both purchased new doses and received them from other countries. At the beginning of the vaccination campaigns, donations came from all over the world, such as China, the United Arab Emirates, India, and Russia. The United Nations-led COVAX initiative provided Oxford/AstraZeneca and Pfizer/BioNTech doses to several African countries. Within this program, the continent received nearly 270 million doses as of January 2022. Moreover, the vaccination campaign has also been an occasion for intra-African solidarity. Senegal has, for instance, donated vaccines to the Gambia, while in January 2021, Algeria announced that it would have shared its supply with Tunisia.

COVID-19 impact on the African economy

The spread of COVID-19 negatively affected socio-economic growth in Africa, with the continent’s Gross Domestic Product (GDP) contracting significantly in 2020. Specifically, Southern Africa experienced the sharpest decline, at minus six percent, followed by North Africa at minus 1.7 percent. Most of Africa’s key economic sectors were hit by the pandemic. The drop in global oil prices led to a crisis in the oil and gas sector. Nigeria, the continent’s leading oil-exporting country, witnessed a considerable decrease in crude oil trade in 2020. Moreover, the shrinking number of international tourist arrivals determined a loss of over 12 million jobs in Africa’s travel and tourism sector. Society has also been substantially affected by COVID-19 on the poorest continent in the world, and the number of people living in extreme poverty was estimated to increase by around 30 million in 2020.

COVID-19 Vaccines Market Outlook

According to our latest research, the global COVID-19 vaccines market size stood at USD 34.2 billion in 2024, reflecting a significant contraction from the pandemic’s peak but still underscoring the ongoing demand for booster shots, variant-specific formulations, and immunization programs. The market is expected to reach USD 14.7 billion by 2033, registering a compound annual growth rate (CAGR) of 9.8% over the forecast period. This trajectory is driven by persistent global immunization efforts, the emergence of new SARS-CoV-2 variants, and the integration of COVID-19 vaccines into routine vaccination schedules.

The primary growth factor for the COVID-19 vaccines market is the continued evolution of the SARS-CoV-2 virus, leading to the emergence of new variants. These variants often exhibit mutations that may partially evade immunity conferred by previous infection or vaccination, necessitating the development and deployment of updated vaccine formulations. Pharmaceutical companies are investing in next-generation vaccines, including multivalent and pan-coronavirus candidates, to address these challenges. Governments and health organizations remain vigilant, maintaining stockpiles and rolling out booster campaigns, especially for high-risk populations such as the elderly and immunocompromised. The integration of COVID-19 vaccines with seasonal influenza programs is also being explored, potentially driving market growth through combined immunization initiatives.

Another crucial driver is the growing emphasis on equitable vaccine access, particularly in low- and middle-income countries. International collaborations, such as COVAX and bilateral donation agreements, have played a vital role in expanding vaccine reach beyond high-income nations. As the acute phase of the pandemic subsides, there is a strategic shift towards sustained immunization efforts, with many countries incorporating COVID-19 vaccines into their national immunization schedules. This long-term approach is expected to stabilize demand and support market growth, albeit at a lower volume compared to the pandemic’s initial years. Additionally, the development of pediatric and variant-adapted vaccines is broadening the addressable market, ensuring ongoing relevance for manufacturers.

Technological advancements in vaccine platforms, particularly mRNA and protein subunit technologies, are reshaping the market landscape. The success of mRNA vaccines has spurred further research into their application for other infectious diseases, creating a pipeline of innovative products. These platforms offer advantages such as rapid adaptability to emerging variants and scalable manufacturing, making them attractive for both public health authorities and commercial stakeholders. The competitive environment is also fostering partnerships between pharmaceutical companies, biotechnology firms, and academic institutions to accelerate research and development. Such collaborations are expected to yield more effective and durable vaccines, further propelling the market’s evolution.

From a regional perspective, North America and Europe continue to lead the market in terms of revenue, owing to robust healthcare infrastructure, high vaccination coverage, and proactive government policies. The Asia Pacific region is witnessing the fastest growth, driven by large population bases, increasing healthcare investments, and expanding immunization programs. Latin America and the Middle East & Africa are gradually improving their vaccination rates, supported by international aid and local manufacturing initiatives. The regional dynamics are influenced by factors such as regulatory approvals, supply chain logistics, and public acceptance of vaccines, which collectively shape the market’s trajectory across different geographies.

Vaccine Type Analysis

The COVID-19 vaccines market is segmented by vaccine type into mRNA vaccines, viral vector vaccines, protein subunit vaccines, inacti

Worldwide Measles Vaccination Rates

Measles Vaccination Rates by Country and Year

By Throwback Thursday [source]

About this dataset

The WHO Region Name column represents the name of the World Health Organization (WHO) region to which each country belongs. The ISO Code column contains the standardized ISO code for each country. The Country Name column specifies the name of each individual country included in this dataset.

The Percentage of Surviving Infants receiving Dose column indicates the percentage of infants who received a specific dose of the measles vaccine and survived. This serves as an important indicator for tracking vaccination rates and overall healthcare effectiveness in relation to preventing measles deaths among infants.

Overall, this dataset provides valuable insights into global measles vaccination rates over a span of several decades. By analyzing this information, researchers and policymakers can assess trends in immunization coverage, identify areas where vaccine uptake is low or improving over time, and guide targeted interventions to increase vaccination rates and reduce infant mortality due to measles infection

How to use the dataset

Introduction:

• Understanding the Columns: a. WHO Region Name: It represents the name of the World Health Organization (WHO) region to which a country belongs. b. ISO Code: It provides the ISO code of each country, which is a standardized three-letter code assigned to represent countries. c. Country Name: This column contains the name of each country involved in the dataset. d. Vaccine: It indicates the type of vaccine administered for measles. e. Year: The year when data was recorded, ranging from 1980 to 2017 (numeric). f. Percentage of Surviving Infants receiving Dose: This represents the percentage value denoting infants who received a specified dose of measles vaccine and survived.

• Navigating through Data:

• To explore data for specific countries or regions, filter by using either 'Country Name' or 'WHO Region Name'.

• Utilize filtering according to specific vaccines if you are interested in studying particular types.

• Selection Tools:

• Use pandas library in Python or similar tools/software platforms like Excel or Google Sheets that support filtering capabilities based on columns mentioned above.

• Employ functions such as dataframe.loc[] in Python's pandas library for extracting desired subsets based on specific filters.

• Data Analysis Ideas: Here are some potential analysis ideas using this dataset:

a) Analyzing Trends Over Time: - Generate line plots/graphs comparing vaccination rates across multiple countries/regions over different years to identify trends and patterns. - Categorize countries/regions by their WHO regions utilizing bar plots/graphs, and analyze how vaccination rates vary within each region over time.

b) Regional Comparisons: - Compare the measles vaccination rates between countries within and across different WHO regions. - Identify the top-performing countries in terms of measles vaccination rates for specific years, regions, or vaccine types.

c) Impact of Vaccine Types: - Assess the impact of different measles vaccines by comparing their adoption rates and effectiveness. - Analyze how the percentage of surviving infants receiving a particular vaccine dose varies over time for individual countries or regions.

d) Outlier Detection: - Explore if there are any significant variations or outliers in measles vaccination rates among different countries or regions. Investigate possible

Research Ideas

• Evaluating the effectiveness of measles vaccination programs: This dataset can be used to analyze the percentage of infants who received the measles vaccine and survived in different countries and regions over time. By comparing this data with information on measles cases and mortality rates, researchers can assess the effectiveness of vaccination programs in preventing measles outbreaks and reducing infant mortality.
• Identifying disparities in vaccine coverage: The dataset can also be used to identify disparities in measles vaccine coverage between countries and regions. By examining the percentage of infants receiving the vaccine across different geographical areas, researchers can identify areas with low coverage rates and target interventions to improve vaccination rates in those regions.
• Assessing trends over time: Since this dataset includes data from 1980 to 2017, it allows for analysis of trends in measles vaccination rates over several decades. Researchers can examine whether there have been improvement...

Approved COVID-19 Vaccines Market Outlook

The global market size for approved COVID-19 vaccines stood at approximately USD 45 billion in 2023 and is projected to reach around USD 78 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.5% during the forecast period. This substantial growth is primarily driven by continuous advancements in vaccine technology, increasing global vaccination drives, and the emergence of new variants necessitating booster doses.

One of the primary growth factors for the approved COVID-19 vaccines market is the ongoing need for booster vaccinations. As new variants of the virus emerge, vaccine manufacturers are continuously enhancing existing vaccines to tackle these variants effectively. This continuous innovation ensures sustained demand for updated vaccines, thereby propelling market growth. Additionally, governments worldwide are investing heavily in vaccination programs to achieve herd immunity, further boosting market size. Initiatives like COVAX, which aim to provide equitable vaccine access, are also significant contributors to market expansion.

Another crucial factor driving market growth is the increased awareness and acceptance of vaccines among the global population. Intensive public health campaigns and educational movements have led to a higher acceptance rate of vaccines, reducing vaccine hesitancy. This trend is particularly significant in emerging economies where initial vaccine skepticism was high. The successful roll-out of initial vaccine doses has built public confidence, thereby increasing the uptake of booster doses and new vaccine variants.

The collaboration between pharmaceutical companies and governments has also played a pivotal role in the growth of the COVID-19 vaccines market. Strategic partnerships for vaccine production, distribution, and administration have streamlined the supply chain, making vaccines more accessible to the public. These collaborations have also facilitated bulk purchasing agreements, which have provided cost advantages and enhanced market penetration across various regions. Moreover, the establishment of new manufacturing facilities and the expansion of existing ones have significantly accelerated vaccine production capabilities.

The development of the COVID-19 RNA Vaccine has been a groundbreaking advancement in the fight against the pandemic. Unlike traditional vaccines, RNA vaccines work by introducing a small piece of genetic material from the virus into the body, prompting an immune response without using a live virus. This innovative approach has allowed for rapid development and deployment, significantly contributing to the global vaccination efforts. The flexibility of RNA technology also enables quick updates to the vaccine to address new variants, ensuring continued protection as the virus evolves. This adaptability has made RNA vaccines a crucial tool in achieving widespread immunity and controlling the spread of COVID-19.

Regionally, North America leads the market due to its advanced healthcare infrastructure and early adoption of vaccination programs. Europe follows closely, with significant contributions from countries like Germany, France, and the UK. The Asia Pacific region is witnessing rapid growth, driven by substantial investments in healthcare infrastructure and large-scale vaccination drives in countries like India and China. Meanwhile, Latin America and the Middle East & Africa are gradually catching up, supported by international aid and improving healthcare systems. The regional diversity ensures a balanced growth outlook for the global market.

Vaccine Type Analysis

The market for approved COVID-19 vaccines is segmented into various types, including mRNA vaccines, vector vaccines, protein subunit vaccines, inactivated vaccines, and others. mRNA vaccines, such as those developed by Pfizer-BioNTech and Moderna, have gained significant traction due to their high efficacy rates and the rapid speed of development. The flexibility of mRNA technology to adapt swiftly to new variants has positioned them as a frontrunner in the market. This segment is expected to continue its dominance, supported by ongoing research and development activities aimed at enhancing vaccine formulations and delivery mechanisms.

Vector vaccines, which use a modified virus to deliver genetic material into cells, represent another significant segment. AstraZeneca and Johnson & Johnson are key players in t